CAS No. |
847829-41-8 |
|---|---|
中文名称 |
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,59S)-59-氨基-38-(3-氨基-3-氧代丙基)-26,47,50-三(4-氨基丁基)-14-[(S)-仲丁基]-11-(2-羧基乙基)-5-(羧甲基)-29,32,35,41,44,53-六(3-胍基丙基)-17,20-双(羟甲基)-60-(4-羟基苯基)-23-异丁基-2,8-二甲基-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58-十九氧代-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-十九氮杂六十烷酸 |
英文名称 |
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,59S)-59-amino-38-(3-amino-3-oxopropyl)-26,47,50-tris(4-aminobutyl)-14-((S)-sec-butyl)-11-(2-carboxyethyl)-5-(carboxymethyl)-29,32,35,41,44,53-hexakis(3-guanidinopropyl)-17,20-bis(hydroxymethyl)-60-(4-hydroxyphenyl)-23-isobutyl-2,8-dimethyl-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58-nonadecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaazahexacontanoic acid |
别名 |
Tat-NR2Baa;L-Alanine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-alanyl-L-α-aspartyl- |
标准英文名 |
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,59S)-59-amino-38-(3-amino-3-oxopropyl)-26,47,50-tris(4-aminobutyl)-14-((S)-sec-butyl)-11-(2-carboxyethyl)-5-(carboxymethyl)-29,32,35,41,44,53-hexakis(3-guanidinopropyl)-17,20-bis(hydroxymethyl)-60-(4-hydroxyphenyl)-23-isobutyl-2,8-dimethyl-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58-nonadecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaazahexacontanoic acid |
分子式 |
C103H184N42O29 |
分子量 |
2474.87 |
精确分子量 |
2473.42 |
SMILES |
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O |
标准SMILES |
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O |
用途 |
Tat-NR2Baa is used as an inactive control peptide in studies investigating the disruption of PSD-95/NMDAR interactions; it serves as a negative control in co-immunoprecipitation assays and in vivo experiments to demonstrate the specificity of Tat-NR2B9c, as it does not affect PSD-95/NR2B binding or neuronal hyperexcitability even at concentrations 100-fold higher than the active peptide Tat-NR2B9c. |
InChIKey |
JGOHJQLBRJDBTQ-RVYJUWCMSA-N |
|
|
评论 |
|---|